DDAVP in the treatment of central diabetes insipidus.
DDAVP, 1-desamino-8-d-arginine-vasopressin, is a synthetic analogue of vasopressin with increased antidiuretic activity and decreased pressor activity. Whereas the antidiuretic-to-pressor ratio of arginine vasopressin is 1, the antidiuretic-to-pressor ratio of DDAVP is 4000. When administered as an intranasal spray, 5 to 20 mug of DDAVP produced eight to 20 hours of antidiuresis in patients with complete central diabetes insipidus. The minimum recommended therapeutic dose resulted in a maximum antidiuresis in most patients. No side effects of the drug were noted in clinical trials. DDAVP thus gives promise of becoming the standard treatment of severe central diabetes insipidus.
D002404:Catheterization / Q000379:methods; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000627:therapeutic use; D003919:Diabetes Insipidus / Q000188:drug therapy* / Q000652:urine; D006801:Humans; D009666:Nose; D013997:Time Factors; D014667:Vasopressins / Q000031:analogs & derivatives*
D014667:Vasopressins; D003894:Deamino Arginine Vasopressin